ESAL

Eisai Co., Ltd.

ESALF·OTC Markets OTCPK

FollowCompareShare

30.790.00 (0.00%)today

At close: Oct 20, 4:00 PM EDT · May be delayed up to 15 min · USD

1D5D1M6MYTD1Y5Y10Y20YAll

MountainLineCandles

Indicators

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close30.79

Open31.50

Day range30.7931.50

52-week range23.8835.00

Off day high−2.25%

Off 52-week high−12.03%

Volume150

Avg. volume (3M)298

Market cap8.69B

EPS (TTM)0.9100

Forward P/E24.44

P/E ratio (TTM)33.84

Dividend yield3.28% (1.01)

Beta (5Y)—

Shares outstanding282.24M

Short interest—

Earnings dateNov 10, 2026

Analyst target—

Profit margin—

Related companies

No related companies yet: the instruments index has no profile for Eisai Co., Ltd..

Latest news

All ESALF news ›

TradingView·5d agoPositive

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

TradingView Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026 TOKYO, Oct 16, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across…

MarketScreener·Oct 7Positive

Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi

China's National Medical Products Administration approved Eisai and Biogen's subcutaneous autoinjector version of anti-amyloid beta protofibril antibody Leqembi as an initiation treatment for... Eisai, Biogen Secure China's Nod for…

MarketScreener·Oct 7Positive

Eisai And Biogen Receive Approval For Leqembi Subcutaneous Formulation As Initiation Treatment For Early Alzheimer's Disease In China

Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration of China has approved the subcutaneous formulation , the anti-amyloid beta protofibril antibody LEQEMBI ...

From articles in the 4Search news index.

In the news

1mentions in 30 days

1with it in the headline

Positivesentiment

Mentioned with

Arcus Biosciences1Astrazeneca1Bristol Myers1Eli Lilly1Endpoints News Mer­ck1Food and Drug Administration1Gilead1Gilead Sciences1

People in the coverage

Afamitresgene Autoleucel1Belzutifan1Bristol Myers1Celcuity1Choueiri1Inluriyo1

Themes

Ben Shapiro1Brian Kilmeade1Buck Sexton1Business & Health1Cancer1Clay Travis1Conservative Talk1FDA1

Most coverage from

1. marketscreener.com1

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.